• U0126-EtOH: Context-Aware MEK1/2 Inhibition

  2026-09-29

  U0126-EtOH is a selective MEK1/2 inhibitor for dissecting MAPK/ERK signaling in neuronal injury, inflammation, and differentiation assays. This guide emphasizes branch-specific interpretation, controls, and protocol decisions rather than treating pathway inhibition as a universal biological outcome.

• SB203580: Practical p38 MAPK Workflows

  2026-09-29

  Use SB203580 to separate p38-driven stress signaling from downstream phenotypes in cell, biochemical, and disease-model experiments. This guide combines practical dosing and controls with a newer dephosphorylation-focused assay strategy inspired by structural kinase research.

• 12-O-tetradecanoyl phorbol-13-acetate (TPA)

  2026-09-28

  A scenario-based guide to using 12-O-tetradecanoyl phorbol-13-acetate (TPA), SKU N2060, for controlled PKC and ERK/MAPK pathway activation in viability, proliferation, cytotoxicity, and signal-transduction workflows. It addresses solvent control, timing, interpretation, storage, and practical product selection.

• Anlotinib: Translating Anti-Angiogenic Mechanisms

  2026-09-28

  Anlotinib hydrochloride offers translational researchers a way to interrogate how coordinated VEGFR2, PDGFRβ, and FGFR1 inhibition reshapes angiogenic signaling. This article connects preclinical evidence to practical assay design, competitive interpretation, and the limits researchers should keep in view.

• Rapamycin in mTOR Pathway Experiments

  2026-09-27

  Use Rapamycin (Sirolimus) as a pathway perturbation to test whether mTOR activity is required for vitamin D-associated changes in neuronal injury models—not simply as a readout of reduced cell viability. This guide turns the juvenile-mouse epilepsy study into a practical, dose-ranging workflow, with controls and troubleshooting to help distinguish pathway effects from toxicity.

• DHT as a Probe of Androgen Signaling and Resistance

  2026-09-26

  Dihydrotestosterone offers a defined way to interrogate androgen receptor activity and its connection to growth-factor signaling. This article connects DHT-responsive experiments with emerging evidence that the bone microenvironment can reshape anti-androgen response, while clarifying what these models do—and do not—establish.

• Sphingosine-1-phosphate (S1P): Signaling & Research

  2026-09-25

  Sphingosine-1-phosphate (S1P) is a bioactive lipid whose effects depend on receptor subtype and cellular context. Research links S1P/S1PR3 signaling with neuronal apoptosis after intracerebral hemorrhage, while product information describes S1PR1-linked endothelial and survival responses.

• Busulfan and the Logic of Ovarian Lineage Tracing

  2026-09-25

  Busulfan is a DNA alkylating agent used to create experimental injury, but injury alone cannot establish that new oocytes have formed. This article examines how dual-recombinase lineage tracing changes the interpretation of ovarian regeneration experiments and what the evidence can—and cannot—show.

• Osteoblast ECM1 Drives Enzalutamide Resistance in Bone PCa

  2026-09-24

  The study identifies osteoblast-derived ECM1 as a bone-microenvironment signal that can promote enzalutamide resistance in prostate cancer cells. It links ECM1 engagement of cell-surface ENO1 to ENO1 Y189 phosphorylation, GRB2/SOS1 recruitment, and MAPK activation, and reports that targeting ECM1 or ENO1 can restore drug sensitivity in the models studied.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-09-24

  The study reports that three inhibitors can both block p38α MAP kinase activity and increase removal of its activation-loop phosphate by the phosphatase WIP1. Structural data suggest that inhibitor binding exposes the phospho-threonine, offering a conformational mechanism for kinase deactivation and a design concept that merits further testing.

• TMAO Activates PERK in Zebrafish NAFLD Progression

  2026-09-23

  A 2024 study reports that dietary trimethylamine N-oxide (TMAO) can induce liver steatosis, inflammation, injury, and fibrosis in zebrafish, with PERK signaling activated in animal and cell models. The findings connect a gut microbiota-related metabolite to liver pathology and provide a framework for testing whether PERK activity contributes causally to disease progression.

• SCH772984: ERK1/2 Inhibitor Workflow

  2026-09-23

  SCH772984 enables selective, ATP-competitive ERK1/2 inhibition for pathway validation, resistance modeling, and combination studies with radiation or ferroptosis-focused assays. Its nanomolar biochemical potency and compatibility with phospho-protein, viability, colony-formation, and xenograft workflows make it useful for connecting MAPK signaling to tumor phenotypes.

• GDC-0994: Selective ERK1/2 Inhibitor

  2026-09-22

  GDC-0994 is a potent, selective ERK1/2 inhibitor for studying MAP kinase signaling in cancer and cholestasis models. Its reported activity against ERK1 and ERK2, combined with preclinical xenograft and zebrafish findings, supports pathway-focused research rather than clinical use.

• tFUS Regulates SHP2 to Limit Stroke Neuroinflammation

  2026-09-22

  This 2025 study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and reduced NLRP3-related neuroinflammation after ischemic stroke. Its combination of a transient MCAO rat model, microglial OGD/R experiments, RNA sequencing, and targeted molecular perturbation provides a useful framework for studying SHP2-dependent neuroprotection.

• Recombinant Human EGF for 3D Spheroid Assays

  2026-09-21

  Use recombinant human EGF to introduce a controlled EGFR-linked variable into 3D glioblastoma spheroid workflows. This guide combines a streamlined 96-well stemness assay with practical dosing, handling, troubleshooting, and orthogonal validation strategies.

8084 records 1/539 page Next 12345 下5页 Last page